RSS

Janssen Biotech

The US FDA has granted 510(k) clearance for the Hydrashift 2/4 daratumumab assay from Sebia, which is intended for use with Hydragel IF for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis. Read more

Technology

Genmab’s licensing partner, Janssen Biotech, has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for the use of daratumumab (DARZALEX) in front line multiple myeloma. Read more

Technology

Biotech company, Proteros, has entered into a new research collaboration with Janssen Biotech (one of the Janssen Pharmaceutical companies of Johnson & Johnson) that is aimed at discovering novel lead compounds against several epigenetic targets Read more

News

Genmab has announced that the FDA has approved the use of DARZALEX (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies. Read more

News

Genmab has announced that its collaboration partner for daratumumab, Janssen Biotech, has decided to not initiate stage 2 of the Phase II study. Read more

News

Johnson & Johnson's Janssen Biotech is to deploy Emulate’s organs-on-chips platform to better predict the potential human response of drug candidates and improve the drug development process under a recently formed research collaboration. Read more

News

Genmab's licensing partner Janssen Biotech has initiated a rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for daratumumab. Read more

News